Semaglutide
Anti-diabetic and anti-obesity medication / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Semaglutide?
Summarize this article for a 10 year old
Semaglutide is an antidiabetic medication used for the treatment of type 2 diabetes and an anti-obesity medication used for long-term weight management.[19][20][21] It is a peptide similar to the hormone glucagon-like peptide-1 (GLP-1), modified with a side chain.[22][23] It can be administered by subcutaneous injection or taken orally.[24][13][14][15] It is sold under the brand names Ozempic[13] and Rybelsus[14] for diabetes, and under the brand name Wegovy for weight loss.[15]
Clinical data | |
---|---|
Pronunciation | /sɛmˈæɡlʊtaɪd/ sem-AG-luu-tyde or /ˌsɛməˈɡluːtaɪd/ SEM-ə-GLOO-tyde |
Trade names | Ozempic, Rybelsus, Wegovy, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a618008 |
License data |
|
Pregnancy category | |
Routes of administration | Subcutaneous, oral |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 89% |
Metabolism | Proteolysis |
Elimination half-life | 7 days |
Duration of action | 63.6 h |
Excretion | Urine and feces |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ECHA InfoCard | 100.219.541 |
Chemical and physical data | |
Formula | C187H291N45O59 |
Molar mass | 4113.641 g·mol−1 |
3D model (JSmol) | |
| |
|
Semaglutide is a glucagon-like peptide-1 receptor agonist.[13][14][15] The most common side effects include nausea, vomiting, diarrhea, abdominal pain, and constipation.[13][16][17][18][25]
It was approved for medical use in the US in 2017.[13][26] In 2021, it was the 90th most commonly prescribed medication in the United States, with more than 8 million prescriptions.[27][28]